Sat, Oct 25, 2014, 7:05 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Alnylam Pharmaceuticals, Inc. Message Board

  • drumss11 drumss11 Jul 18, 2013 1:09 PM Flag


    Insiders have been selling since February up thru July 12th. Michael Mason (VP) sold 14,000+ shares at
    $50 on July 12th. I was going to buy this stock on the latest pullback but will wait until the insiders come back in. IMO this could be around $35. Great potential in ALNY but not at the current price and I believe the run-
    up was overdone.

    Sentiment: Hold

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • up !

      Sentiment: Sell

    • ALNY is just coming back to true value. After the July 11 Phase 1 press lots of people thought they saw a chance for a quick buck. Phase 1 announcements are worthless. No big pharma will look at contracting after just a Phase1 announcement. Not even after a Phase 2. ALNY will be dead in the water for at least a year and a half. In the meanwhile there are many rising stocks that did the rise on something other than a company pump, they did it on results. I wouldn't touch this stock with a ten foot pole until it is in the threes. Buy stocks on results, not on company pumps.

    • Your post does not make sense. "Great potential but not at the current price". If there is great potential then it will be way above its current price eventually.

      I hear what you are saying. You are saying that you think it will go lower. But let's be clear. If there is 'great potential' then it is a good buy right here. If there is not great potential, then why even buy @ $30?

    • you are spot on. i like the company. but compare it's valuation to isis and tkmr. overpriced. and heavy insider selling a red flag. i'll buy in the 30s if it drops that low.

93.84+2.03(+2.21%)Oct 24 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Cabela's Incorporated
NYSEFri, Oct 24, 2014 4:00 PM EDT